(Q43428609)

23 November 2017

title

Which fluoroquinolones are suitable for the treatment of urinary tract infections? (English)

1 reference

23 November 2017

Naber KG

1

1 reference

23 November 2017

publication date

1 April 2001

1 reference

International Journal of Antimicrobial Agents

23 November 2017

published in

1 reference

23 November 2017

volume

17

1 reference

23 November 2017

issue

4

1 reference

23 November 2017

page(s)

331-341

1 reference

Classification of fluoroquinolones

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Evaluation of data from susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

The comparative pharmacokinetics of five quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Pharmacokinetics of lomefloxacin in renally compromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

1 reference

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Introduction to biofilm

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Bacterial biofilms and catheters in experimental urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Short-term therapy of acute uncomplicated cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900362-9

7 January 2021

10.1016/S0924-8579(00)00362-9

Identifiers

DOI

1 reference

23 November 2017

1 reference